A 15 Week, Randomized, Double Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose, Safety And Efficacy Study Of Pregabalin In Adolescents (12-17 Years Old) With Fibromyalgia

Trial Profile

A 15 Week, Randomized, Double Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose, Safety And Efficacy Study Of Pregabalin In Adolescents (12-17 Years Old) With Fibromyalgia

Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Pregabalin (Primary)
  • Indications Fibromyalgia
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 12 Mar 2015 Primary endpoint has not been met according to the results published in the Pfizer Media Release. (Change from baseline to week 15 in mean pain diary score)
    • 12 Mar 2015 Top-line results published in the Pfizer Media Release.
    • 11 Jan 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top